Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

Dr. Dorairaj Prabhakaran

General Cardiology

Dr. Pugazhendhi Vijayaraman

EP · Geisinger

Discover your community
Stay current
A profile that represents you
Find your people

About Roon Privacy Terms

RM

Dr. Robert Mentz

Cardiology · Advanced Heart Failure & Transplantation

Duke University

robertm

Durham, NC, USA

Aug 19, 2025Journal Article

Characterizing real-world use of vericiguat in the United States.

Written by 1 Roon author & 8 others

Via Journal of Cardiac Failure

Research

Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis

2025

Via Cardiovascular Diabetology

Research

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

2025

Via European Heart Journal

Aug 28, 2025Journal Article

Assessing Benefit in Patients With Heart Failure and Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification.

Written by 1 Roon author & 17 others

Via Journal of Cardiac Failure

Research

Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR

2025

Via Journal of the American College of Cardiology

Research

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

2025

Via Lancet

Research

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

2025

Via Lancet

Research

Reduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials

2025

Via Research and Practice in Thrombosis and Haemostasis

Sep 1, 2025Editorial

The Value of Community in Heart Failure.

Written by 1 Roon author & 1 other

Via Journal of Cardiac Failure

Research

Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute HF: The REHAB-HF Trial

2025

Via JACC. Heart Failure

Research

Early in-hospital treatment of acute heart failure. Part 2 of the international expert opinion series on AHF management

2025

Via ESC Heart Failure

Research

Early diagnosis and treatment of acute heart failure in prehospital and emergency settings. Part 1 of the International Expert Opinion Series on acute heart failure management

2025

Via European Journal of Emergency Medicine

Research

Acute heart failure care - a consensus series of an international experts' group

2025

Via European Journal of Heart Failure

Research

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial

2025

Via European Journal of Heart Failure

Sep 28, 2025Journal Article

Optimizing Pre-to-Post Discharge Transition of Care in Patients Hospitalized for Heart Failure - Part 3 of the International Expert Opinion Series on Acute Heart Failure Management.

Written by 2 Roon authors & 23 others

Via Journal of Cardiac Failure